SNCA and synucleinopathy: Therefore, a successful immune response by the vaccine candidates that recognizes or binds to aggregated/amyloid alpha‐synuclein in the hemizygous TgM83+/−‐mouse brain could have important implications for the development of new immunotherapies for synucleinopathies.